Transaction to create a well-funded, clinical-stage biotechnology company advancing engineered macrophages for the treatment of cancer and other serious disorders
Combined company expected to have approximately $180 million of cash, cash equivalents and marketable securities at close, including $30 million from a concurrent financing by Carisma, which is expected to fund the combined company through 2024
Cash runway of combined company expected to enable multiple clinical readouts across Carisma programs
https://finance.yahoo.com/news/sesen-bio-carisma-therapeutics-announce-120000658.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.